for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (vol 385, pg 1873, 2015)

Hillmen P.; Robak T.; Janssens A.

首页> 外文期刊>The Lancet >for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (vol 385, pg 1873, 2015)

【24h】

for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (vol 385, pg 1873, 2015)

机译：补充1学习调查人员。 Hollambucil plus ofatumumab与氯镁在以前未经治疗的慢性淋巴细胞白血病患者中（补充1）：一个随机的多方形，开放标签第3阶段试验（Vol 385，PG 1873,2015）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2016年第10026期|共1页
作者
Hillmen P.; Robak T.; Janssens A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献

1. for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (vol 385, pg 1873, 2015) [J] . Hillmen P., Robak T., Janssens A. The Lancet . 2016,第10026期

机译：补充1学习调查人员。 Hollambucil plus ofatumumab与氯镁在以前未经治疗的慢性淋巴细胞白血病患者中（补充1）：一个随机的多方形，开放标签第3阶段试验（Vol 385，PG 1873,2015）
2. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial [J] . Hillmen Peter, Robak Tadeusz, Janssens Ann, The Lancet . 2015,第9980期

机译：先前未接受治疗的慢性淋巴细胞性白血病患者中的氯丁酸苯丙酸联合奥他木单抗与单用苯丁酸氮芥（比较项1）：一项随机，多中心，开放标签的3期试验
3. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (vol 20, pg 43, 2019) [J] . Moreno C., Greil R., Demirkan F. The lancet oncology . 2019,第1期

机译：Ibrutinib Plus Obinutuzumab与氯苯脲加上Obinutuzumab在慢性淋巴细胞白血病的一线治疗中（亮起）：多期，随机，开放标签，第3阶段试验（Vol 20，PG 43,2019）
4. Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data [O] . Anna Maria Frustaci, Alessandra Tedeschi, Paola Picardi, 2016

机译：Ofatumumab联合苯丁酸氮芥作为不适合的慢性淋巴细胞性白血病患者的一线治疗：COMPLEMENT1和其他单克隆抗体关联数据的分析
5. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL [O] . Hillmen, Peter, Janssens, Ann, Babu, K Govind, 2016

机译：在以前未治疗的CLL患者的COmpLEmENT 1试验中，与健康相关的生活质量和患者报告的ofatumumab加苯丁酸氮芥与苯丁酸氮芥单药治疗的结果

for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (vol 385, pg 1873, 2015)

著录项

相似文献

相关主题

期刊订阅